

- from smooth muscle cell membranes. *Inter J Biochrom* 1998;4:1-13.
71. Migonney V, Lacroix MD, Ratner BD, Jozefowicz M. Silicone derivatives for contact lenses: functionalization, chemical characterization, and cell compatibility assessment. *J Biomater Sci Polym Edn* 1995;7:265-275.
 72. Logeart-Avramoglou D, Jozefowicz J. Carboxymethyl benzylamide sulfonate dextrans (CMDBS), a family of biospecific polymers endowed with numerous biological properties: a review. *J Biomed Mater Res* 1999;48:578-590.
 73. Vaudaux P, Avramoglou T, Letourneur D, Lew DP, Jozefowicz J. Inhibition by heparin and derivatized dextrans of *Staphylococcus aureus* adhesion to fibronectin-coated biomaterials. *J Biomater Sci Polym Edn* 1992;4:89-97.
 74. Francois P, Letourneur D, Lew DP, Jozefowicz J, Vaudaux P. Inhibition by heparin and derivatized dextrans of *Staphylococcus epidermidis* adhesion to in vitro fibronectin-coated or explanted polymer surfaces. *J Biomater Sci Polym Edn* 1999;10:1207-1221.
 75. de Raucourt E, Mauray S, Chaubet F, Maiga-Revel O, Jozefowicz M, Fischer AM. Anticoagulant activity of dextran derivatives. *J Biomed Mater Res* 1998;41:49-57.
 76. Neyts J, Reymen D, Letourneur D, Jozefowicz J, Schols D, Este J, et al. Differential antiviral activity of derivatized dextrans. *Biochem Pharmacol* 1995;50:743-751.
 77. Carre V, Mbemba E, Letourneur D, Jozefowicz J, Gattegno L. Interactions of HIV-1 envelope glycoproteins with derivatized dextrans. *Biochim Biophys Acta* 1995;1243:175-180.
 78. Seddiki N, Mbemba E, Letourneur D, Ylisastigui L, Benjouad A, Saffar L, et al. Antiviral activity of derivatized dextrans on HIV-1 infection of primary macrophages and blood lymphocytes. *Biochim Biophys Acta* 1997;1362:47-55.
 79. Thomas H, Maillet F, Letourneur D, Jozefowicz J, Fischer E, Kazatchkine MD. Sulfonated dextran inhibits complement activation and complement-dependent cytotoxicity in an in vitro model of hyperacute xenograft rejection. *Mol Immunol* 1996;33:643-648.
 80. Prigent-Richard S, Cansell M, Vassy J, Viron A, Puvion E, Jozefowicz J, et al. Fluorescent and radiolabeling of polysaccharides: binding and internalization experiments on vascular cells. *J Biomed Mater Res* 1998;40:275-281.
 81. Letourneur D, Champion J, Slaoui F, Jozefowicz J. In vitro stimulation of human endothelial cells by derivatized dextrans. *In Vitro Cell Dev Biol* 1993;29:67-72.
 82. Bagheri-Yarmand R, Kourbali Y, Rath AM, Vassy R, Martin A, Jozefowicz J, et al. Carboxymethyl benzylamide dextran blocks angiogenesis of MDA-MB435 breast carcinoma xenografted in fat pad and its lung metastases in nude mice. *Cancer Res* 1999;59:507-510.
 83. Bittoun P, Bagheri-Yarmand R, Chaubet F, Crepin M, Jozefowicz J, Fermandjian S. Effects of the binding of a dextran derivative on fibroblast growth factor 2: secondary structure and receptor-binding studies. *Biochem Pharmacol* 1999;57:1399-1406.
 84. Bagheri-Yarmand R, Kourbali Y, Morere JF, Jozefowicz J, Crepin M. Inhibition of MCF-7ras tumor growth by carboxymethyl benzylamide dextran: blockage of the paracrine effect and receptor binding of transforming growth factor beta 1 and platelet-derived growth factor-BB. *Cell Growth Differ* 1998;9:497-504.
 85. Bagheri-Yarmand R, Kourbali Y, Mabilat C, Morere JF, Martin A, Lu H, et al. The suppression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumour angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7). *Br J Cancer* 1998;78:111-118.
 86. Vaudaux P, Lew DP, Waldvogel FA. Host factors predisposing to and influencing therapy of foreign body infections. In: Bisno AL, Waldvogel FA, eds. *Infections Associated With Indwelling Medical Devices*. 2nd ed. Washington, DC: American Society for Microbiology; 1994:1-29.
 87. Francois P, Schrenzel J, Stoerman-Chopard C, Favre H, Herrmann M, Foster TJ, et al. Identification of plasma proteins adsorbed on hemodialysis tubing that promote *Staphylococcus aureus* adhesion. *J Lab Clin Med* 2000;135:32-42.
 88. Yamada KM. Fibronectin domains and receptors. In: Mosher DF, ed. *Fibronectin*. San Diego, CA: Academic Press; 1989:48-121.

Risk Factors and Outcome for Vancomycin-Resistant and -Susceptible Enterococcal Bacteremia

Gina Pugliese, RN, MS
Martin S. Favero, PhD

Bhavnani and coinvestigators, from the Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital/Kaleida Health, Buffalo, New York, conducted a study of National Nosocomial Resistance Surveillance Group participants from 22 hospitals across the United States. They reviewed medical records for hospitalized patients with vancomycin-resistant enterococcal (VRE) or vancomycin-susceptible enterococcal (VSE) bacteremia to identify risk factors associated with the acquisition of VRE bacteremia, describe genetic traits of VRE strains, and identify factors predic-

tive of clinical outcome. VRE cases were matched to VSE controls within each institution. Multiple logistic regression (LR) and classification and regression tree (CART) analysis were used to probe for factors associated with VRE bacteremia and clinical outcome. A total of 150 matched-pairs of VRE cases and VSE controls were collected from 1995 to 1997. Using LR, the following were found to be highly associated with VRE bacteremia: history of AIDS, positive HIV status, or drug abuse (odds ratio [OR], 9.58); prior exposure with parenteral vancomycin (OR, 8.37); and liver transplant history (OR, 6.75). CART analysis revealed that isolation of *Enterococcus faecium*, prior vancomycin exposure, and serum creatinine

values ≥ 1.1 mg/dL were predictors of VRE bacteremia. Greater proportions of clinical failure (60% vs 40%; $P < .001$) and all-cause mortality (52% vs 27%; $P < .001$) were seen in patients with VRE versus VSE bacteremia. Results from both LR and CART indicated that patients with persisting enterococcal bacteremia, intubation at baseline, higher APACHE II scores, and VRE bacteremia were at greater risk for poor outcome.

FROM: Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. *Diagn Microbiol Infect Dis* 2000;36:145-158.